Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 4, 2015, Pages 674-679

  Ye, Le Chi ^a,b   Wei, Ye ^b   Zhu, De Xiang ^b   Chen, Tao ^b   Xu, Jianmin ^b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Cetuximab; Colorectal liver metastasis; Early tumor shrinkage

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DRUG ERUPTION; DRUG SAFETY; EARLY TUMOR SHRINKAGE; FOLLOW UP; HUMAN; LIVER SURGERY; MAJOR CLINICAL STUDY; METASTASIS RESECTION; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; GENETICS; KIRSTEN MURINE SARCOMA VIRUS; LIVER NEOPLASMS; LIVER RESECTION; PATHOLOGY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CETUXIMAB; COLORECTAL NEOPLASMS; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; KIRSTEN MURINE SARCOMA VIRUS; LIVER NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84924769392     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12847     Document Type: Article

References (26)

1. Chibaudel B, Tournigand C, Andre T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther. Adv. Med. Oncol. 2012; 4: 75-89.
2. Lievre A, Bachet JB, Boige V etal. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008; 26: 374-379.
3. Van Cutsem E, Kohne CH, Hitre E etal. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009; 360: 1408-1417.
4. De Roock W, Claes B, Bernasconi D etal. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-762.
5. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011; 12: 594-603.
6. Stintzing S, Kapaun C, Laubender RP etal. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. International journal of cancer J Int Cancer. 2013; 132: 236-245.
7. Eisenhauer EA, Therasse P, Bogaerts J etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009; 45: 228-247.
8. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat. Rev. 2009; 35: 309-321.
9. Modest DP, Laubender RP, Stintzing S etal. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol. 2013; 52: 956-962.
10. Giessen C, Laubender RP, Fischer von Weikersthal L etal. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci. 2013; 104: 718-724.
11. Piessevaux H, Buyse M, De Roock W etal. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann. Oncol. 2009; 20: 1375-1382.
12. Piessevaux H, Buyse M, Schlichting M etal. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 2013; 31: 3764-3775.
13. Ricotta R, Vanzulli A, Moroni M etal. Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. Clin. Colorectal Cancer 2013; 12: 45-53.
14. Suzuki C, Blomqvist L, Sundin A etal. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann. Oncol. 2012; 23: 948-954.
15. Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist 2011; 16: 859-867.
16. Birchard KR, Hoang JK, Herndon JE Jr, Patz EF Jr. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2009; 115: 581-586.
17. Grothey A, Hedrick EE, Mass RD etal. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J. Clin. Oncol. 2008; 26: 183-189.
18. Ye LC, Liu TS, Ren L etal. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J. Clin. Oncol. 2013; 31: 1931-1938.
19. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2006; 107: 431-434.
20. Moore MJ, Goldstein D, Hamm J etal. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007; 25: 1960-1966.
21. Dingli D, Pacheco JM, Nowakowski GS etal. Relationship between depth of response and outcome in multiple myeloma. J. Clin. Oncol. 2007; 25: 4933-4937.
22. Perrotte P, Matsumoto T, Inoue K etal. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 1999; 5: 257-265.
23. Debucquoy A, Haustermans K, Daemen A etal. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J. Clin. Oncol. 2009; 27: 2751-2757.
24. Heinemann V, Fischer von Weikersthal L, Decker T etal. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). 2013:Suppl:abstr LBA3506.
25. De Bruyne S, Van Damme N, Smeets P etal. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br. J. Cancer 2012; 106: 1926-1933.
26. Chung WS, Park MS, Shin SJ etal. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. AJR Am. J. Roentgenol. 2012; 199: 809-815.